Usefulness of noninvasive methods for the study of bronchial inflammation in the control of patients with asthma

International Archives of Allergy and Immunology

Volumn 166, Issue 1, 2015, Pages 1-12

  Muñoz, Xavier ^a,b,d   Bustamante, Victor ^e   Lopez Campos, José Luis ^d,f   Cruz, María Jesús ^a,d   Barreiro, Esther ^c,d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL DE BASURTO   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Eosinophils; Exhaled breath condensate; Exhaled nitric oxide; Induced sputum; Volatile organic compounds

Indexed keywords

NITRIC OXIDE; PROSTANOID; VOLATILE ORGANIC COMPOUND; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CYTOKINE;

ASTHMA; BRONCHIAL INFLAMMATION; BRONCHUS DISEASE; DISEASE CONTROL; EOSINOPHIL; EXHALATION; EXHALED BREATH CONDENSATE; EXPIRED AIR; HUMAN; META ANALYSIS; MINIMALLY INVASIVE PROCEDURE; NON INVASIVE PROCEDURE; OXIDATIVE STRESS; PH; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SYSTEMATIC REVIEW; TEMPERATURE; BREATH ANALYSIS; CHEMISTRY; CYTOLOGY; FEMALE; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SPUTUM;

ANTI-INFLAMMATORY AGENTS; ASTHMA; BIOLOGICAL MARKERS; BREATH TESTS; CYTOKINES; EOSINOPHILS; EXHALATION; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NITRIC OXIDE; PROGNOSIS; SPUTUM;

EID: 84926408876     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000371849     Document Type: Review

References (116)

1. Kazani S, Israel E: Update in asthma 2011. Am J Respir Crit Care Med 2012; 186:35-40.
2. Bedolla-Barajas M, Morales-Romero J, Ro-bles-Figeroa M, Fregoso-Fregoso M: Asthma in late adolescents of Western Mexico: prevalence and associated factors. Arch Broncho-neumol 2013; 49:47-53.
3. Global Initiative for Asthma: Global strategy for asthma management and prevention 2012. http://www.ginasthma.com.
4. Martínez-Moratalla J, Almar E, Anto JM: Changes in asthma treatment in the Spanish Cohort of the European Community Respiratory Health Survey (ECRHS) from 1991-2001: a perspective over time. Arch Broncho-neumol 2013; 49:113-118.
5. Martinez FD, Vercelli D: Asthma. Lancet 2013; 382:1360-1372.
6. García Gomez M, Urbanos Garrido R, Casta-ñeda Lopez R, Lopez Menduiña P: Direct health care costs of occupational asthma in Spain: an estimation from 2008. Arch Bron-choneumol 2012; 48:355-361.
7. Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, En-right PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Szefler SJ, Sullivan SD, Thomas MD, Wenzel SE, Reddel HK: A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32:545-554.
8. Guía Española para el Manejo del Asma (GEMA 2009). http://www.gemasma.com.
9. Haldar P, et al: Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-224.
10. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, D'Agostino R Jr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER; National Heart, Lung, and Blood Institute's Severe Asthma Research Program: Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-323.
11. Muñoz X, Sanchez-Vidaurre S, Roca O, Torres F, Morell F, Cruz MJ: Bronchial inflammation and hyperresponsiveness in well controlled asthma. Clin Exp Allergy 2012; 42: 1321-1328.
12. Wenzel SE, Schwart LB, Langmack EL, Hal-liday JL, Trudeau JB, Gibbs, RL, Chu HW: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-1008.
13. Volbeda F, Broekema M, Lodewijk ME, Hylkema MN, Reddel HK, Timens W, Post-ma DS, ten Hacken NH: Clinical control of asthma associates with measures of airway inflammation. Thorax 2013: 68:19-24.
14. Wenzel SE: Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-813.
15. Bruselle G, Maes T, Bracke KR: Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013: 19: 977-979.
16. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Brad-ding P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
17. Corren J, Lemanske RF, Hanania NA, Koren-blat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG: Lebriki-zumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-1098.
18. Wenzel SE, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G: Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455-2466.
19. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343-373.
20. Sont JK, Willems LN, Bel EH, van Kricken JH, Vandenbroucke JP, Sterk PJ: Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999; 159:1043-1051.
21. Perpiña M, García Río F, Álvarez Gutierrez FJ, Cisneros Serrano C, Compte Torrero L, Entre-nas Costa LM, Melero Moreno C, Rodríguez Nieto MJ, Torrego Fernández A; Spanish Society of Pulmonology and Thoracic Surgery (SEPAR): Guidelines for the study of nonspecific bronchial hyperresponsiveness in asthma. Arch Bronconeumol 2013; 49:432-446.
22. Davies AR, Hancox RJ: Induced sputum in asthma: diagnostic and therapeutic implications. Curr Opin Pulm Med 2013; 19:60-65.
23. Brightling CE: Cough due to asthma and non-asthmatic eosinophilic bronchitis. Lung 2010; 188(suppl 1):S13-S17.
24. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE: Standardised methodology of sputum induction and processing. Eur Respir J 2002; (suppl 37):1s-2s.
25. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE: Indices of airway inflammation in induced sputum: reproduc-ibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154:308-317.
26. Wadsworth S, Sin D, Dorscheid D: Clinical update on the use of biomarkers of airway inflammation in the management of asthma. J Asthma Allergy 2011; 4:77-86.
27. Carroll N, Carello S, Cooke C, James A: Airway structure and inflammatory cells in fatal attacks of asthma. Eur Respir J 1996; 4:709-715.
28. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, Bleecker ER; National Heart, Lung, and Blood Institute Severe Asthma Research Program: Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010; 123:1028-1036.
29. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM: Mepolizumab for predni-sone-dependent asthma with sputum eosino-philia. N Engl J Med 2009; 360:985-993.
30. Bacci E, Cianchetti S, Bartoli M, Dente FL, Di Franco A, Vagaggini B, Paggiaro P: Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 2006; 129:565-572.
31. Shannon J, Ernst P, Yamauchi Y, Olivenstein R, Lemiere C, Foley S, Cicora L, Ludwig M, Hamid Q, Martin JG: Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133:420-426.
32. Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, Hamid Q: T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009; 123:1185-1187.
33. Butler CA, Heaney LG: Neurogenic inflammation and asthma. Inflamm Allergy Drug Targets 2007; 6:127-132.
34. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ: Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353:2213-2214.
35. Green RH, Brightling CE, McKenna S, Harga-don B, Parker D, Bradding P, Wardlaw AJ, Pavord ID: Asthma exacerbations and sputum eosinophil count: a randomized controlled trial. Lancet 2002; 360:1715-1721.
36. Chlumsky J, Striz I, Terl M, Vondracek J: Strategy aimed at reduction of sputum eosin-ophils decreases exacerbation rate in patients with asthma. J Int Med Res 2006; 34:129-139.
37. Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemière C, Pizzichini E, Cartier A, Hussack P, Goldsmith CH, Laviolette M, Parameswaran K, Hargreave FE: Determining asthma treatment by monitoring sputum cell counts effect on exacerbations. Eur Respir J 2006; 27:483-494.
38. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB: A systematic review and met-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67:199-208.
39. Hanxiang N, Jiong Y, Yanwei C, Dunshuang W, Xuhong D, Xiaojun W, Changsheng L: Persistent airway inflammation and bronchial hyperresponsiveness in patients with totally controlled asthma. Int J Clin Pract 2008; 62: 599-605.
40. Madhuban AA, Driessen JM, Brusse-Keizer MG, van Aalderen WM, de Jongh FH, Thio BJ: Association of the asthma control questionnaire with exercise-induced bronchocon-striction. J Asthma 2011; 48:275-278.
41. Papaporfyriou A, Tseliou E, Loukides S, Kos-tikas K, Bakakos P: Noninvasive evaluation of airway inflammation in patients with severe asthma. Ann Allergy Asthma Immunol 2013; 110:316-321.
42. Ricciardolo FLM: Multiple roles of nitric oxide in the airways. Thorax 2003; 58:175-182.
43. Nathan C, Xie QW: Nitric oxide synthases: roles, tolls, and controls. Cell 1994; 78:915-918.
44. Ricciardolo FL: Revisiting the role of exhaled nitric oxide in asthma. Curr Opin Pul Med 2014; 20:53-59.
45. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med 2005; 171:912-930.
46. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications: An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184:602-615.
47. Jouaville LF, Annesi-Maesano I, Nguyen LT, Bocage AS, Bedu M, Caillaud D: Interrelationships among asthma, atopy, rhinitis and exhaled nitric oxide in a population-based sample of children. Clin Exp Allergy 2003; 33: 1506-1511.
48. Strunk RC, Szefler SI, Philips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske RF Jr; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute: Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 2003; 112:883-892.
49. Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID: The use of exhaled nitric oxide concentrations to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35:1175-1179.
50. Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, Shields MD: Exhaled nitric oxide correlates with airways eosinophils in childhood asthma. Thorax 2002; 57:383-387.
51. Lemière C, Ernst P, Olivenstein R, Yamauchi Y, Govindaraju K, Ludwig MS, Martin JG, Hamid Q: Airway inflammation assessed by invasive and non-invasive means in severe asthma: eosinophilic and non-eosinophilic phenotypes. J Allergy Clin Immunol 2006; 118:1033-1039.
52. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A: Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:418-424.
53. Soler-Cataluña JJ, Cosio B, Izquierdo JL, Lopez-Campos JL, Marin JM, Agüero R, Baloira A, Carrizo S, Esteban C, Galdiz JB, González MC, Miravitlles M, Monsó E, Montemayor T, Morera J, Ortega F, Peces-Barba G, Puente L, Rodríguez JM, Sala E, Sauleda J, Soriano JB, Viejo JL: Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012; 48;331-337.
54. Brightling CE, Symon FA, Birring SS, Bradd-ing P, Wardlaw AJ, Pavord ID: Comparison of airway immunopathology of eosinophils bronchitis and asthma. Thorax 2003; 58:528-532.
55. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, Herbison GP, Taylor DR: Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172:453-459.
56. Quirce S, Bobolea I, Domínguez-Ortega J, Barranco P: Future biologic therapies in asthma. Arch Bronconeumol 2014; 50: 355-361.
57. Hanania NH, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W: Exploring the effects of omali-zumab in allergic asthma: an analysis of bio-markers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804-811.
58. Dweik RA, Sorkness RL, Wenzel S, Hammel J, Curran-Everett D, Comhair SA, Bleecker E, Busse W, Calhoun WJ, Castro M, Chung KF, Israel E, Jarjour N, Moore W, Peters S, Teague G, Gaston B, Erzurum SC; National Heart, Lung, and Blood Institute Severe Asthma Research Program: Use of exhaled nitric oxide measurement to identify a reactive at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181:1033-1041.
59. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, ten Brinke A, Bel EH: Severe adult-onset asthma: a distinct phe-notype. J Allergy Clin Immunol 2013; 132: 336-341.
60. Erkoçoglu M, Kaya A, Ozcan C, Akan A, Vezir E, Azkur D, Kara O, Demirel F, Ginis T, Civelek E, Kocabas CN: The effect of obesity on the level of fractional exhaled nitric oxide in children with asthma. Int Arch Allergy Immunol 2013; 162:156-162.
61. Schneider A, Schwarzbach J, Faderl B, Welker L, Karsch-Völk M, Jörres RA: FENO measurement and sputum analysis for diagnosing asthma in clinical practice. Respir Med 2013; 107:209-218.
62. Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P, Taylor DR: Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional test. Am J Respir Crit Care Med 2004; 169:473-478.
63. Pedrosa M, Cancelliere N, Barranco P, Lopez-Carrasco V, Quirce S: Usefulness of exhaled nitric oxide for diagnosing asthma. J Asthma 2010; 47:817-821.
64. Sandrini A, Taylor DR, Thomas PS, Yates DH: Fractional exhaled nitric oxide in asthma: an update. Respirology 2010; 15:57-70.
65. Dupont LJ, Demedts MG, Verleden GM: Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest 2003; 123:751-756.
66. Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S: Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax 2005; 60: 383-388.
67. Perez de Llano LA: Nitric oxide (NO) in managing asthma. Arch Bronconeumol 2012; 48: 35-36.
68. Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, Taylor DR: The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med 2001; 164: 738-743.
69. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-2173.
70. Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, Kattan M, Pongracic JA, Teach SJ, Bloomberg GR, Egg-leston PA, Gruchalla RS, Kercsmar CM, Liu AH, Wildfire JJ, Curry MD, Busse WW: Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008; 372:1065-1072.
71. de Jongste JC, Carraro S, Hop WC; CHARISM Study Group, Baraldi E: Daily telemonitoring of exhaled bitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009; 179:93-97.
72. Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR: Effects of steroid therapy in inflammatory cell subtypes in asthma. Thorax 2010; 65:384-390.
73. Perez de Llano JA, Carballada F, Castro Añón O, Pizarro M, Golpe R, Baloira A, Vázquez Caruncho M, Boquete M: Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma. Eur Respir J 2010; 35:1221-1227.
74. Rahman I, Kelly F: Biomarkers in breath condensate: a promising new non-invasive technique in free radical research. Free Radic Res 2003; 1253-1266.
75. Kinnula VI: Production and degradation of oxygen metabolites during inflammatory states in the human lung. Curr Drug Targets Inflamm Allergy 2005; 4:465-470.
76. Moser B, Bodrogi F, Eibl G, Lechner M, Rie-der J, Lirk P: Mass spectrometric profile of exhaled breath-field study by PTR-MS. Respir Physiol Neurobiol 2005; 14 5: 295-300.
77. Röck F, Barsan N, Weimar U: Electronic nose: current status and future trends. Chem Rev 2008; 108:705-725.
78. Dragonieri S, Schot R, Mertens BJ, Le Cessie S, Gauw SA, Spanevello A, Resta O, Willard NP, Vink TJ, Rabe KF, Bel EH, Sterk PJ: An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007; 120:856-862.
79. Fons N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, Cheung D, Bel EH, Sterk PJ: Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2008; 180: 1076-1082.
80. Ibrahim B, Basanta M, Cadden P, Sinh D, Douce D, Woodcock A, Fowler SJ: Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax 2011; 66: 804-809.
81. Robroeks ChM, van Berkel JJ, Jöbsis Q, van Schooten FJ, Dallinga JW, Wouters EF, Dom-peling E: Exhaled volatile organic compounds predict exacerbations of childhood asthma in 1-year prospective study. Eur Respir J 2013; 42:98-106.
82. Jareño JJ, Muñoz MA, Carrillo B, Maldonado JA, de Grande I, Aguilar A, Civera C, Gutierrez C, Callol LM: Volatile organic compounds in exhaled breath in a healthy population: effect of tobacco smoking. Arch Bronconeumol 2013; 49:457-461.
83. Paredi P, Kharitonov SA, Barnes PJ: Faster rise of exhaled breath temperature in asthma. Am J Respir Crit Care Med 2002; 165:181-184.
84. Piacentini GL, Bodini A, Zerman L, Costella S, Zanolla L, Peroni DG, Boner AL: Relationship between exhaled air temperature and exhaled nitric oxide in childhood asthma. Eur Respir J 2002; 20:108-111.
85. Popov TA, Dunev S, Kralimarkova TZ, Krae-va S, DuBuske LM: Evaluation of a simple potentially individual device for exhaled breath temperature measurement. Respir Med 2007; 101:2044-2055.
86. Piacentini GL, Bodini A, Peroni D, Ress M, Costella S, Boner AL: Exhaled air temperature and eosinophil airway inflammation in allergic asthmatic children. J Allergy Clin Immunol 2004; 114:202-204.
87. Kralimarkova TZ, Popov TA: Exhaled breath temperature: broadening the horizons. Int J Tuberc Lung Dis 2014; 18:250-251.
88. Svensson H, Bjermer L, Tufvesson E: Exhaled breath temperature in asthmatics and controls after eucapnic voluntary hyperventila-tion and methacholine challenge test. Respiration 2014; 87:149-157.
89. Paredi P, Kharitoov SA, Barnes PJ: Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respir Res 2005; 6: 15.
90. Svensson H, Nilsson D, Bjermer L, Tufvesson E: Exhaled breath temperature after exercise in asthmatics and controls. Respiration 2012; 84:283-290.
91. Hoffmeyer F, Raulf-Heimoth M, Brüning T: Exhaled breath condensate and airway inflammation. Curr Opin Allergy Clin Immunol 2009; 9:16-22.
92. Horvath I, Hunt J, Barnes PJ, Alving K, Antc-zak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jöbsis Q, Las-kowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate: Exhaled breath condensate; methodological recommendations and unresolved questions. Eur Respir J 2005; 26:523-548.
93. Kostikas K, Koutsokera A, Papiris S, Gour-goulianis KI, Loukides S: Exhaled breath condensate in patients with asthma: implications for application in clinical practice. Clin Exp Allergy 2008; 38:557-565.
94. Vaughan J, Ngamtrakulpanit L, Pajewski TN, Turner R, Nguyen TA, Urban P, Hom S, Gas-ton B, Hunt J: Exhaled breath condensate pH is a robust and reproducible assay of airway acidity. Eur Respir J 2003; 22:889-894.
95. Prieto L, Ferrer A, Palop J, Domenech J, Llu-sar R, Rojas R: Differences in exhaled breath condensate pH measurements between samples obtained with two commercial devices. Respir Med 2007; 101:1715-1720.
96. Cruz MJ, Sánchez-Vidaurre S, Romero PV, Morell F, Muñoz X: Impact of age on pH, 8-isoprostane, and nitrogen oxides in exhaled breath condensate. Chest 2009; 135:462-467.
97. Antus B, Barta I, Kullmann T, Lazar Z, Valyon M, Horvath I, Csiszer E: Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 1492-1497.
98. Tomasiak-Lozowska MM, Zietkowski Z, Prz-eslaw K, Tomasiak M, Skiepko R, Bodzenta-Lukaszyk A: Inflammatory markers and acid-base equilibrium in exhaled breath condensate of stable and unstable asthma patients. Int Arch Allergy Immunol 2012; 159:121-129.
99. Kostikas K, Papatheodorou G, Ganas K, Psathakis K, Panagou P, Loukides S: pH in expired breath condensate of patients with inflammatory airways diseases. Am J Respir Crit Care Med 2002; 165:1364-1370.
100. Muñoz X, Velasco MI, Culebras M, Roca O, Morell F, Cruz MJ: Utility of exhaled breath condensate pH for diagnosing occupational asthma. Int Arch Allergy Immunol 2012; 159:313-320.
101. Sanchez-Vidaurre S, Cruz MJ, Gomez-Ollés S, Morell F, Muñoz X: Diagnostic utility of exhaled breath condensate analysis in conjunction with specific inhalation challenge in individuals with suspected work-related asthma. Ann Allergy Asthma Immunol 2012; 108:151-156.
102. Ciencewicki J, Trivedi S, Kleeberger SR: Ox-idants and the pathogenesis of lung diseases. J Allergy Clin Immunol 2008; 122:456-468.
103. Loukides S, Bouros D, Papatheodorou G, Panagou P, Siafakas NM: The relationship among hydrogen peroxide in expired breath condensate, airway inflammation, and asthma severity. Chest 2002; 212:338-346.
104. Horvath I Donnelly LE, Kiss A, Balint B, Kharitonov SA, Barnes PJ: Exhaled nitric oxide and hydrogen peroxide concentrations in asthmatic smokers. Respiration 2004; 7: 463-468.
105. Horvath I, Donnelly LE, Kiss A, Kharitonov SA, Lim S, Chung KF, Barnes PJ: Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Am J Respir Crit Care Med 1998; 158:1042-1046.
106. Antezak A, Nowak D, Shariati B, Król M, Pi-asecka G, Kurmanowska Z: Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients. Eur Respir J 1997; 10:1235-1241.
107. Teng Y, Sun P, Zhang J, Yu R, Bai J, Yao X, Huang M, Adcock IM, Barnes PJ: Hydrogen peroxide in exhaled breath condensate in patients with asthma. Chest 2011; 140:108-116.
108. Murata K, Fujimoto K, Kitaguchi Y, Horiu-chi T, Kubo K, Honda T: Hydrogen peroxide content and pH of expired breath condensate from patients with asthma and COPD. COPD 2014; 11:81-87.
109. Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Khartonov SA, Barnes PJ: Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216-220.
110. Piotrowski WJ, Majewski S, Marczak J, Kur-manowska Z, Górski P, Antczak A: Exhaled breath 8-isoprostane as a marker of asthma severity. Arch Med Sci 2012; 8:515-520.
111. Antczak A, Montuschi P, Kharitonov S, Gorski P, Barnes PJ: Increased exhaled cys-teinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166:301-306.
112. Battaglia S, den Hertog H, Timmers MC, La-ceroms SP, Vignola AM, Rabe KF, Bellia V, Hiemstra PS, Sterk PJ: Small airways function and molecular markers in exhaled air in mild asthma. Thorax 2005; 60:639-644.
113. Kostikas K, Papatheodorou G, Psathakis K, Panagou P, Loukides S: Prostaglandin E2 in the expired breath condensate of patients with asthma. Eur Respir J 2003; 22:743-747.
114. Loukides S, Kontogianni K, Hillas G, Hor-vath I: Exhaled breath condensate in asthma: from bench to bedside. Curr Med Chem 2011; 18:1432-1443.
115. Robroeks CM, van Vliet D, Jobsis O, Braek-ers R, Rijkers GT, Wodzig WK, Bast A, Zim-mermann LJ, Dompeling E: Prediction of asthma exacerbations in children: results of a one-year prospective study. Clin Exp Allergy 2012; 42:792-798.
116. Kazani S, Planaguma A, Ono E, Bonini M, Zahid M, Marigowda G, Wechsler ME, Levy BD, Israel E: Exhaled breath condensate eicosanoid levels associate with asthma and its severity. J Allergy Clin Immunol 2013; 132:547-553.